Clinical Impact of Peridevice Leak Following Left Atrial Appendage Closure

Left atrial appendage closure (LAAO) has consolidated as a valid strategy for thromboembolic event prevention in patients with non-valvular atrial fibrillation (NVAF), especially in patients with oral anticoagulation contraindication. 

However, the presence of peridevice leak (PDL) following LAAO has raised questions about its long term clinical impact. 

The OCEAN-LAAC, a Japanese multicenter study, prospectively looked at PDL repercussion by transesophageal EKG immediately after procedure and during clinical followup. This analysis focused mainly on leaks deemed “acceptable” (≤3 mm).  

The primary outcome was incidence of thromboembolic events – transient ischemic attack (TIA), ischemic stroke or systemic embolization – within two years after procedure. Secondary end point was all cause mortality at 2 years. 

Read also: Evolution of Renal Denervation at 24 Months.

Data from 1397 patients were analyzed. 6% presented PDL, mean patient age was 77.5, and they were mostly men; mean CHA₂DS₂-VASc score was 4 and HAS-BLED was 3. PDL was observed mostly in patients with elevated baseline heart rate, larger LAA ostial diameter and in most Watchman 2.5 devices, vs FLX.

Ischemic event incidence was significantly higher in patients with any PDL (Gray’s Test, p=0.0036), including those ≤3 mm (sHR: 3.53; CI95%: 1.37–9.04; p=0.016). Altogether, data show the presence of PDL is associated with nearly four times more ischemic events (sHR: 4.25; CI95%: 1.91–9.44; p<0.001).

However, this increase of thromboembolic events does not translate into higher global mortality, probably because of the non-fatal nature of many TIA and ischemic strokes, as well as timely intervention. 

Conclusion

These results suggest that leaks detected after procedure, including those deemed acceptable in size, might have relevant clinical impact on patient prognosis. 

Original Title: Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry.

Reference: Saito T, Tsuruta H, Kajino A, Iwata J, Sakata S, Ryuzaki T, Sago M, Tanaka S, Chatani R, Hachinohe D, Naganuma T, Ohno Y, Tani T, Okamatsu H, Mizutani K, Watanabe Y, Izumo M, Saji M, Mizuno S, Ueno H, Kubo S, Shirai S, Nakashima M, Asami M, Yamamoto M, Ieda M, Hayashida K; OCEAN‐LAAC investigators. Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry. J Am Heart Assoc. 2025 Aug 18:e044422. doi: 10.1161/JAHA.125.044422. Epub ahead of print. PMID: 40820980.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...